Clinical Trial: A Study of Tadalafil for Duchenne Muscular Dystrophy

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy

Brief Summary: The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.

Detailed Summary:
Sponsor: Eli Lilly and Company

Current Primary Outcome: Change From Baseline in Six Minute Walk Distance (6MWD) in Meters [ Time Frame: Baseline, Week 48 ]

Original Primary Outcome: Change From Baseline in Six Minute Walk Distance (6MWD) in Meters [ Time Frame: Baseline, Week 48 ]

Current Secondary Outcome:

• Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score [ Time Frame: Baseline, Week 48 ]
  The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
• Change From Baseline in Timed Function Tests in Seconds [ Time Frame: Baseline, Week 48 ]
  Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.
• Time to Persistent 10% Worsening in 6MWD [ Time Frame: Baseline through Week 48 ]
  Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.
• Time to Persistent 10% Worsening in Timed Function Tests (TFT) [ Time Frame: Baseline through Week 48 ]

  Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is >110% of the baseline time and all the time values observed afterward are also >110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period.

  Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.

• Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores [ Time Frame: Baseline, Week 48 ]
  PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of "0" represents a poor outcome/worse health, while "100" is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.
• Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil [ Time Frame: Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose ]
  The data reported are population estimate and inter-patient variability.

Original Secondary Outcome:

• Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score [ Time Frame: Baseline, Week 48 ]
• Change From Baseline in Timed Function Tests in Seconds [ Time Frame: Baseline, Week 48 ]
• Time to Persistent 10% Worsening in 6MWD [ Time Frame: Baseline through Week 48 ]
• Time to Persistent 10% Worsening in Timed Function Tests [ Time Frame: Baseline through Week 48 ]
• Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores [ Time Frame: Baseline, Week 48 ]
• Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil [ Time Frame: 1 Hour up to 24 Hours Postdose; Weeks 4, 12, 24 and 36 ]

Dates:
Date Received: May 24, 2013
Date Started: September 2013
Date Completion:
Last Updated: January 10, 2017
Last Verified: January 2017